Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria
- PMID: 36312504
- PMCID: PMC9602233
- DOI: 10.12998/wjcc.v10.i29.10413
Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria
Abstract
Liver transplantation (LT) for hepatocellular carcinoma is still a hot topic, and the main factor that is associated with the success of treatment is to determine the patients who will benefit from LT. Milan criteria have been defined 25 years ago and still is being used for patient selection for LT. However, in living donor LT, the Milan criteria is being extended. Current criteria for patient selection do not only consider morphologic characteristics such as tumor size and number of tumor nodules but also biologic markers that show tumor aggressiveness is also being considered. In the present review article, we have summarized all the criteria and scoring systems regarding LT for hepatocellular carcinoma. All criteria have 5-year overall survival rates that were comparable to the Milan Criteria and ranged between 60%-85%. On the other hand, it was seen that the recurrence rates had increased as the Milan criteria were exceeded; the 5-year recurrence rates ranged between 4.9% to 39.9%. Treatment of hepatocellular carcinoma needs a multidisciplinary approach. Ideal selection criteria are yet to be discovered. The same is true for treatment modalities. The goal will be achieved by a harmonic interplay between basic science researchers and clinicians.
Keywords: Expanded Malatya criteria; Hepatocellular carcinoma; Liver transplantation; Milan criteria.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Similar articles
-
Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.World J Gastroenterol. 2018 Aug 28;24(32):3626-3636. doi: 10.3748/wjg.v24.i32.3626. World J Gastroenterol. 2018. PMID: 30166858 Free PMC article. Review.
-
Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation?J Gastrointest Cancer. 2020 Dec;51(4):1107-1113. doi: 10.1007/s12029-020-00482-0. J Gastrointest Cancer. 2020. PMID: 32857265 Review.
-
Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review.J Clin Med. 2021 Aug 31;10(17):3932. doi: 10.3390/jcm10173932. J Clin Med. 2021. PMID: 34501381 Free PMC article. Review.
-
How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?J Hepatol. 2013 Aug;59(2):279-84. doi: 10.1016/j.jhep.2013.04.006. Epub 2013 Apr 12. J Hepatol. 2013. PMID: 23587474 Clinical Trial.
-
Role of [18F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):257-263. doi: 10.1016/s1499-3872(17)60011-0. Hepatobiliary Pancreat Dis Int. 2017. PMID: 28603093
Cited by
-
Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study.BMC Surg. 2023 Jan 11;23(1):6. doi: 10.1186/s12893-022-01892-6. BMC Surg. 2023. PMID: 36631851 Free PMC article.
-
Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review.J Clin Transl Hepatol. 2025 Apr 28;13(4):327-338. doi: 10.14218/JCTH.2024.00432. Epub 2025 Feb 24. J Clin Transl Hepatol. 2025. PMID: 40206277 Free PMC article. Review.
-
Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?J Clin Med. 2024 Dec 30;14(1):144. doi: 10.3390/jcm14010144. J Clin Med. 2024. PMID: 39797227 Free PMC article.
-
Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations.World J Clin Cases. 2023 Mar 16;11(8):1753-1760. doi: 10.12998/wjcc.v11.i8.1753. World J Clin Cases. 2023. PMID: 36970008 Free PMC article.
-
Effect of ABO blood group on postoperative overall survival and recurrence-free survival rate in patients with hepatocellular carcinoma after hepatectomy: a multi-center retrospective cohort study.BMC Surg. 2023 Oct 24;23(1):324. doi: 10.1186/s12893-023-02236-8. BMC Surg. 2023. PMID: 37875876 Free PMC article.
References
-
- Global Cancer Observatory. Globocan 2020. Dec 2020. [cited 10 March 2022]. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf .
-
- Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet. 1999;354:1636–1639. - PubMed
-
- Bruix J, Fuster J, Llovet JM. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl. 2003;9:700–702. - PubMed
-
- Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant. 2008;8:839–846. - PubMed
-
- Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020;104:1136–1142. - PubMed
Publication types
LinkOut - more resources
Full Text Sources